SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Balfour JA, Goa KL. Dolasetron: a review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs. 1997; 54: 273298.
  • 2
    Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 2000; 18: 163173.
  • 3
    Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer. 2002; 10: 519522.
  • 4
    American Society of Health-System Pharmacists therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm. 1999; 56: 729764.
  • 5
    Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999; 17: 29712994.
  • 6
    Ettinger DS, Bierman PJ, Bradbury B, et al. The NCCN antiemesis clinical practice guidelines in oncology (Version 1. 2002) [monograph online]. Available from URL: http://www.nccn.org/physician_gls/index.html [accessed April 16, 2003].
  • 7
    Johnston D, Latreille J, Laberge F, et al. Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy (HDCP). A study by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) [abstract]. Proc Am Soc Clin Oncol. 1995; 14: 529.
  • 8
    Kaizer L, Warr D, Hoskins P, et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a Phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994; 12: 10501057.
  • 9
    Hesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer. 2001; 9: 350354.
  • 10
    Wong EH, Clark R, Leung E, et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol. 1995; 114: 851859.
  • 11
    Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogeric, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol. In press.
  • 12
    Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1992; 1: 331-340.
  • 13
    Miller RC, Galvan M, Gittos MW, van Giersbergen PL, Moser PC, Fozard JR. Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors. Drug Dev Res. 1993; 28: 8793.
  • 14
    Piraccini G, Stolz R, Tei M, Macciocchi A. Pharmacokinetic features of a novel 5-HT3-receptor antagonist: palonosetron (RS 25259-197) [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 400a.
  • 15
    Aventis Pharmaceuticals. Anzemet (dolasetron mesylate injection) [package insert]. Bridgewater, NJ: Aventis, 2002.
  • 16
    GlaxoSmithKline. Zofran (ondansetron hydrochloride) injection [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2001.
  • 17
    Roche Laboratories. Kytril (granisetron hydrochloride) injection [package insert]. Nutley, NJ: Roche, 2000.